Topiramate Augmentation in Bulimia Nervosa Partial Responders

Status Withdrawn

Clinical Trial Summary

The goal of this study is to generate pilot data exploring the addition of an augmentation (additional) medication to patients suffering from bulimia nervosa who have responded but not had complete symptom resolution with a course of standard medication treatment.

Clinical Trial Description

The aim of this study is to determine whether the addition of an augmentation medication (topiramate 200mg/d) will confer additional reductions in symptomatology in BN patients who have received six weeks of standard pharmacological treatment with fluoxetine 60 mg/day or its equivalent and had a partial response but are not in symptomatic remission. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00988481
Study type	Interventional
Source	Neuropsychiatric Research Institute, Fargo, North Dakota
Contact
Status	Withdrawn
Phase	Phase 4
Start date	September 2009
Completion date	September 2010

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT04174703` - Preparing for Eating Disorders Treatment Through Compassionate Letter-Writing	N/A
Terminated	`NCT04278755` - Binge Eating & Birth Control	Phase 2
Withdrawn	`NCT02978742` - Evaluating and Implementing a Smartphone Application Treatment Program for Bulimia Nervosa and Binge Eating Disorder	N/A
Completed	`NCT00184301` - A Comparison Study of Treatments Given to Patients With Concurrent Eating Disorder and Personality Disorder.	N/A
Completed	`NCT00522769` - Cognitive Behavioral Therapy to Treat Bulimia Nervosa in Adolescents	Phase 1/Phase 2
Completed	`NCT00304187` - Effectiveness of Antibiotic Treatment for Reducing Binge Eating and Improving Digestive Function in Bulimia Nervosa	Phase 2
Recruiting	`NCT04409457` - Self-Control in Bulimia Nervosa	N/A
Recruiting	`NCT05509257` - Naltrexone Neuroimaging in Teens With Eating Disorders	Early Phase 1
Recruiting	`NCT05862389` - Study on the Mechanism of Eating Disorder
Recruiting	`NCT05937243` - Identifying Effective Technological-based Augmentations to Enhance Outcomes From Self-help Cognitive Behavior Therapy for Binge Eating	N/A
Recruiting	`NCT05728021` - Smartphone-based Aftercare for Inpatients With Bulimia Nervosa	N/A
Completed	`NCT03781921` - The Neural Bases of Emotion Regulation in Bulimia Nervosa
Completed	`NCT02553824` - FDA Approved Medication to Reduce Binge Eating and/or Purging	Phase 1
Terminated	`NCT04041024` - Decision-making and Risk-taking in Bulimia	N/A
Completed	`NCT04265131` - Emotion Regulation in Eating Disorders: How Can Art Therapy Contribute to Treatment Outcome?	N/A
Recruiting	`NCT06431854` - Evaluation of a New Treatment Program for Adolescents With Eating Disorders: MINERVA Program	N/A
Recruiting	`NCT02960152` - Periodontal Impact of Eating Disorders (the PERIOED Study)	N/A
Completed	`NCT00916071` - Association Between Attention Deficit Hyperactivity Disorder and Bulimia Nervosa in Outpatients With Eating Disorders	N/A
Terminated	`NCT00308776` - Cholecystokinin for Reducing Binge Eating in People With Bulimia Nervosa	N/A
Completed	`NCT03712748` - Online Imaginal Exposure	N/A